Myomo Announces MyoPro Availability in 16 New U.S. Locations
May 24 2018 - 8:00AM
Business Wire
Includes Efforts in Jacksonville, Florida, and
Scottsdale, Arizona, to Serve Patients from Nationally Acclaimed
Health Systems
Myomo®, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
wearable medical robotics company that offers increased
functionality for those suffering from neurological disorders and
upper limb paralysis, today announced agreements with leading
orthotics and prosthetics practices to bring MyoPro® availability
to 16 new U.S. locations.
Today’s announcement includes an agreement with Limb Lab, an
independently owned and operated boutique prosthetic and orthotic
company, to cooperate in two new markets: Jacksonville, Florida,
and Scottsdale (Phoenix area), Arizona. Several medical and
rehabilitation centers with national acclaim have locations in
Jacksonville and Scottsdale. Myomo has recently hired business
development managers in both Phoenix and Florida to support
expected growth.
Limb Lab’s existing facilities in Rochester and Mankato, Minn.,
and La Crosse, Wisc., are well-established centers of excellence
serving a range of patients, including those suffering from upper
limb paralysis as a result of stroke or other neuromuscular disease
or injury. Limb Lab frequently fits MyoPro devices for patients who
have experienced brachial plexus injuries (BPI) and whose arms are
impaired.
Carrie Kaster of Kansas City, Missouri, was fitted with a MyoPro
by Limb Lab after a severe motorcycle accident damaged her brachial
plexus and after surgery. “My arm was useless, even after surgery,”
said Carrie. “I was given the option to amputate. Now, with MyoPro,
I can again prepare meals, feed myself and perform many other
activities of daily living. It has changed my life.”
Additional new agreements include Reach Orthotics &
Prosthetics in Newport News, Chesapeake, Gloucester, and
Williamsburg, Virginia; Teter Orthotics & Prosthetics in
Traverse City and Grand Rapids, Michigan; and Springer Prosthetics
and Orthotics in Lansing and Mount Pleasant, Michigan.
Through other partnerships, MyoPro is also available in Chicago;
Indianapolis; Milwaukee; St. Louis and Kansas City, Missouri; and
Wichita, Kansas.
Most commercial healthcare plans, multiple Medicaid plans, and
many workers’ compensation and Medicare Advantage plans have
covered the MyoPro based on medical necessity and the potential to
reduce healthcare costs. Eligible veterans may receive a MyoPro
through their local VA Medical Center.
About MyomoMyomo, Inc. is a wearable medical robotics
company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb
orthosis designed to support the arm and restore function to the
weakened or paralyzed arms of patients suffering from CVA stroke,
brachial plexus injury, traumatic brain or spinal cord injury, ALS
or other neuromuscular disease or injury. It is currently the only
marketed device that, sensing a patient’s own EMG signals
through non-invasive sensors on the arm, can restore an
individual’s ability to perform activities of daily living,
including feeding themselves, carrying objects and doing household
tasks. Many are able to return to work, live independently and
reduce their cost of care. Myomo is headquartered in Cambridge,
Massachusetts, with sales and clinical professionals across the
U.S. For more information, please visit www.myomo.com.
Forward-Looking StatementsThis press release contains
forward-looking statements regarding the Company's future business
expectations, including the therapeutic benefits of our products,
expected growth of our business, the expected benefits of expanded
MyoPro availability and continued coverage of MyoPro by healthcare
plans, which are subject to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are only predictions and may differ
materially from actual results due to a variety of factors. Our
actual results could differ materially from those anticipated in
these forward looking statements for many reasons, including,
without limitation, risks related to regulatory approval and market
acceptance of our products, and that we may not realize the
expected benefits of our agreements with the orthotics and
prosthetics practices described in this press release, and the
other risk factors contained in our filings made with
the Securities and Exchange Commission. More information about
factors that potentially could affect Myomo's financial results is
included in Myomo's filings with the Securities and Exchange
Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only
as of the date made. The Company disclaims any obligation
subsequently to revise any forward-looking statements to reflect
events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180524005227/en/
For Myomo:ir@myomo.comorInvestor Relations:PCG
AdvisoryVivian Cervantes,
646-863-6274vivian@pcgadvisory.comorPublic
Relations:GreenoughRachel Robbins,
617-275-6521rrobbins@greenough.biz
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024